A 2026 Canadian survey highlights how patients and clinicians navigate vaginal hormone therapy for genitourinary syndrome of menopause, focusing on convenience.
The Published Data on Treatment Choices
Conversations about physical comfort during midlife intimacy often center on a mix of local therapies and over-the-counter options, yet the search for the right solution can feel solitary. On October 12, 2026, an article published in Patient Preference and Adherence outlined these dynamics. The report examined a Canadian survey on vaginal hormone therapy for genitourinary syndrome of menopause. The published data details how gynecologists and patients currently navigate treatment decisions.
These findings provide an important window into modern clinical discussions. The study highlights a common reliance on practical solutions like moisturizers and lubricants alongside localized hormones. Patients and clinicians must weigh several factors to find the right balance of comfort and convenience. By examining these survey results, individuals can better understand why treatment recommendations often vary from person to person.
Surveying Patients and Specialists
The article reports on the PRIME survey. This was a noninterventional survey-based quality assessment conducted in Canada during March and April 2025. The researchers included 13 gynecologists who maintain menopause-focused practices. The patient cohort included 119 individuals diagnosed with genitourinary syndrome of menopause.
These patients were divided into two specific groups for analysis. The first group included 54 individuals who were eligible for vaginal hormone therapy but had not yet been prescribed it. The second group consisted of 65 patients who were currently receiving vaginal hormone therapy. The researchers used descriptive statistics and chi-square tests for subgroup comparisons.
Symptoms Drive the Need for Conversation
The survey provides a detailed look at the physical realities of genitourinary syndrome of menopause. In the group of patients not previously prescribed vaginal hormone therapy, 61 percent reported vaginal discomfort, dryness, itching or burning. Exactly 50 percent reported experiencing pain during sexual intercourse. These numbers show that patients deal with a wide range of physical symptoms rather than a single uniform experience.
A subgroup analysis within this survey offered interesting demographic details. Among the previously untreated patients, changes in sexual function were reported by 54 percent of patients under the age of 60. In contrast, only 27 percent of patients aged 60 or older reported these changes. The authors reported a P value of 0.04 for this specific finding.
However, this is a subgroup result from a small survey. It is not definitive evidence that age alone explains changes in sexual function. You can learn more about these physical shifts by reviewing resources on genitourinary changes after menopause.
Prior Treatments Often Shift After Consultation
Before their specialist consultation, many patients relied on readily available options. Among the survey participants not previously prescribed vaginal hormone therapy, 33 percent reported using lubricants. Another 24 percent reported using moisturizers. Interestingly, 33 percent reported using no therapy at all for their symptoms before the consultation.
A detailed discussion with a menopause specialist frequently changed these initial routines. After their consultation, 96 percent of these previously untreated patients experienced a change in their treatment plan. The survey noted that 78 percent of this group initiated vaginal hormone therapy. Among those starting a new localized hormone treatment, the most common choices were estradiol inserts at 33 percent.
Estrogen creams and DHEA ovules were each chosen by 19 percent of the initiating group. Clinicians must balance clinical efficacy with patient preferences when recommending these specific treatments. The clinicians surveyed estimated that vaginal moisturizers or lubricants were their most commonly prescribed category at 49 percent. The article also separated these nonhormonal estimates, reporting mean prescribing patterns of 31 percent for lubricants and 18 percent for moisturizers.
Clinician Prescribing Habits and Priorities
These figures represent clinician estimates rather than a population-wide measurement of actual treatment use. Their estimated prescribing patterns for vaginal estrogen options included estrogen creams at 35 percent and estradiol inserts at 26 percent. They estimated prescribing tablets at 20 percent and vaginal DHEA ovules at 12 percent. Clinicians factored practical issues heavily into these prescribing habits.
When selecting inserts and rings, clinicians often prioritized convenience and comfort. For creams and tablets, they frequently focused on patient preference and cost or insurance coverage. When clinicians recommended DHEA ovules, they most often cited ease of use, androgen action on vaginal tissue and a low perceived risk of systemic absorption.
Patient Satisfaction and Practical Considerations
Patients value practical features just as much as medical efficacy. The survey noted that patients ranked ease of use, a rapid onset of action and a low risk of systemic hormone absorption as their top treatment considerations. Patients already using vaginal hormone therapy generally viewed their treatments positively. Within this treated group, 78 percent considered their therapy to be somewhat or very effective.
Most patients also reported high compliance with their daily or weekly routines. In fact, 83 percent of these treated individuals stated they used the therapy as directed at least 80 percent of the time. Additionally, 77 percent were somewhat or very satisfied with the ease of use. This suggests that localized treatments can fit well into an individual's lifestyle when selected carefully.
The Desire to Switch Remains High
Despite this general satisfaction, practical frustrations remain quite common. The survey found that 65 percent of treated patients reported at least one issue with their current therapy. The most frequent complaints included messiness at 22 percent and a lack of improvement in vulvar symptoms at 15 percent. Cost or affordability was an issue for 14 percent of the users in this group.
These daily frustrations significantly impact long-term treatment plans. Because of these challenges, 77 percent of the treated group said they would consider switching therapies. They most often desired an option with less mess or residual discharge, which was cited by 29 percent. Easier application was a priority for 28 percent of the group.
A Snapshot Rather Than a Definitive Answer
While the PRIME survey offers valuable insights, its design comes with important limitations. The patient sample was identified exclusively through participating gynecologists with menopause-focused practices. The authors clearly note that these results may not represent everyone with genitourinary syndrome of menopause across Canada. Patients managed in primary care settings might have entirely different treatment experiences.
The study was also mostly descriptive in its approach. It did not objectively assess vaginal tissue health or formally classify clinical success and failure for the participants. Readers should therefore view these results as a snapshot of reported experiences at a specific point in time. It should never be presented as a national prevalence metric or absolute proof that a particular treatment caused a specific outcome.
The study also revealed a fascinating disconnect between clinician and patient views on treatment habits. Clinicians identified adherence to the medication as a major management challenge. Meanwhile, treated patients self-reported very high levels of compliance with their prescribed routines. The survey cannot prove whether this self-reported use matched actual use over time, as the two measures might simply capture different aspects of the daily treatment routine.
Funding and administrative support for this study also provide necessary context for the reader. Knight Therapeutics funded the survey work, the writing assistance and the publication fees for the final article. The published article lists three company employees among the credited authors. Furthermore, participating gynecologists were compensated for their administrative work and the time spent obtaining patient consent.
These funding disclosures help readers evaluate the sponsor's role in a single survey, though they do not automatically invalidate the published statistics. Analyzing these dynamics allows individuals to approach future clinical data with a balanced, objective perspective. Ultimately, the survey serves as one piece of a much larger clinical puzzle.
Placing the Update in a Broader Context
This survey's findings reflect broader conversations within sexual wellness, where established practices increasingly frame physical comfort as a standard part of midlife care. Rather than treating this single Canadian survey as a final, definitive answer, readers should view it as a real-world reflection of ongoing clinical trends. The results demonstrate how specialized practitioners already utilize a tiered approach, starting with accessible moisturizers and incorporating targeted hormones when needed.
The survey reinforces existing knowledge that maintaining comfort often requires adjusting treatments over time. This aligns seamlessly with broader educational frameworks that prioritize clear patient-clinician dialogue for evolving physical needs. Individuals looking for a comprehensive overview of how symptom management evolves can review a practical guide to vaginal and vulvar health after menopause. To further understand how physical shifts connect with desire, readers can review why menopause hormone changes do not mean an inevitable loss of sexual fulfillment.
Preparing for a Practical Discussion
Understanding these survey results can help individuals prepare for more effective clinical conversations. Genitourinary syndrome of menopause can cause dryness, itching, burning and pain during physical intimacy. The survey data shows that patients report a wide range of physical symptoms rather than one uniform complaint. Recognizing your specific physical symptoms is the first vital step toward finding reliable relief.
When you meet with a clinician, expect the conversation to cover multiple practical angles. A discussion might address your current symptoms, any products you have already tried, and your preferred treatment format. Affordability, insurance coverage and the need for follow-up appointments are also very common discussion points during these visits. These factors reflect the precise issues examined in the survey, though they do not represent a strict medical checklist for every appointment.
Knowing that convenience and messiness are common clinical topics can make it easier to voice your own preferences clearly. Patients who communicate their daily frustrations often find it easier to secure a treatment plan that works for their specific lifestyle.
Finding Comfort Without Compromise
Conversations about physical comfort during midlife intimacy do not have to remain a solitary search. The October 12, 2026 article in Patient Preference and Adherence highlights how often patients update their routines once they speak with a specialist. You do not have to settle for daily treatments that are messy, difficult to apply or prohibitively expensive. By bringing practical concerns directly into the exam room, you can partner with your clinician to find a solution that fits seamlessly into your life.
Identifying a practical treatment for midlife vaginal discomfort requires a clear grasp of your medical options, and Sexential delivers the evidence-aware insights necessary to guide this decision. We address your confusion about changes in libido, desire or arousal by connecting biological symptoms to your daily reality, ensuring you can make informed choices about your long-term sexual wellbeing.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
